top of page
  • Completed

NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2

Updated: Jun 13, 2022

CHAMPION 2

NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2)


champion 2 myeloma trial

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2)


The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.


Sponsor

Amgen

 

ClinicalTrials.gov Identifier: NCT01980589


Official Title: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

First Posted: November 11, 2013


Click here for details on ClinicalTrials.gov

 


 

Drug: Carfilzomib

Drug: Cyclophosphamide

Drug: Dexamethasone

 

Clin Lymphoma Myeloma Leuk;2017

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Conclusion: Carfilzomib in combination with cyclophosphamide and dexamethasone is effective and has manageable toxicity for patients with newly diagnosed MM.

 

Locations

United States, California

United States, Indiana

United States, Maryland

United States, New York

United States, Tennessee

United States, Texas

United States, Virginia






コメント


Posts Archive
bottom of page